Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 7/20 | 0.56 |
| ▸ | HRH1 | P35367 | 5/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | HRH2 | P25021 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12986232 | 0.88 | CHRM3 (0.54) | CHRM3HRH1HTR2ACHRM2CHRM1 | |
| SCHEMBL19212507 | 0.87 | CHRM3 (0.51) | CHRM3HRH1HTR2ACHRM2CHRM1 | |
| SCHEMBL724557 | 0.82 | CHRM3 (0.63) | CHRM3HRH1HTR2ACHRM2CHRM1 | |
| SCHEMBL724558 | 0.82 | CHRM3 (0.63) | CHRM3HRH1HTR2ACHRM2CHRM1 | |
| SCHEMBL14988049 | 0.81 | CHRM3 (0.58) | CHRM3HRH1HTR2ACHRM2CHRM1 | |
| SCHEMBL12986836 | 0.79 | CHRM3 (0.52) | CHRM3HRH1HTR2ACHRM2CHRM1 | |
| SCHEMBL6757073 | 0.76 | CHRM3 (0.55) | CHRM3HRH1HTR2ACHRM2CHRM1 | |
| SCHEMBL1809355 | 0.76 | CHRM3 (0.55) | CHRM3HRH1HTR2ACHRM2CHRM1 | |
| SCHEMBL1809358 | 0.76 | CHRM3 (0.55) | CHRM3HRH1HTR2ACHRM2CHRM1 | |
| SCHEMBL5614313 | 0.76 | CHRM3 (0.65) | CHRM3HRH1HTR2ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759420-B2 | Inhalable particles | CRYSTEC LTD (GB) | 2023-09-19 | — | — | US | disclosed |
| US-20220331243-A1 | INHALABLE PARTICLES | CRYSTEC LTD (GB) | 2022-10-20 | — | — | US | disclosed |
| US-11351115-B2 | Inhalable particles | CRYSTEC LTD (GB) | 2022-06-07 | — | — | US | disclosed |
| US-20200230053-A1 | Inhalable Particles | CRYSTEC LTD (GB) | 2020-07-23 | — | — | US | disclosed |
| EP-3104848-B1 | INHALABLE PARTICLE FORMULATIONS COMPRISING AN ANTIMUSCARINIC AGENT | CRYSTEC LTD (GB) | 2020-05-06 | — | — | EP | disclosed |
| CN-106163505-B | Improvements relating to inhalable particles | 科瑞思特有限公司 | 2020-04-24 | — | — | CN | disclosed |
| CN-104530417-B | A kind of multiple functionalized H types polyethyleneglycol derivative and preparation method thereof | 厦门赛诺邦格生物科技股份有限公司 | 2017-09-08 | — | — | CN | disclosed |
| WO-2017137955-A1 | NOVEL (R) AND RAC 3-(2-(ALLYLOXY)-5-METHYLPHENYL)-N,N-DIISOPROPYL-3- PHENYLPROPAN-1-AMINE AND ITS USE FOR SYNTHESIS OF (R) AND RAC-2-(3- (DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4-(HYDROXYMETHYL)PHENOL | CELESTIS PHARMACEUTICALS PVT. LTD. (IN) | 2017-08-17 | — | — | WO | disclosed |
| US-20170065589-A1 | METHODS OF TREATING OR PREVENTING PRETERM LABOR | VISCO ANTHONY G (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170056325-A1 | Improvements Relating To Inhalable Particles | CRYSTEC LTD (GB) | 2017-03-02 | — | — | US | disclosed |
| EP-3104848-A1 | IMPROVEMENTS RELATING TO INHALABLE PARTICLES | Crystec Ltd. (GB) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015121664-A1 | IMPROVEMENTS RELATING TO INHALABLE PARTICLES | CRYSTEC LTD (GB) | 2015-08-20 | — | — | WO | disclosed |
| US-20120220655-A1 | CRYSTALLINE FORMS OF FESOTERODINE FUMARATE AND FESOTERODINE BASE | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2012-08-30 | — | — | US | disclosed |
| EP-2459520-A1 | CRYSTALLINE FORMS OF FESOTERODINE FUMARATE AND FESOTERODINE BASE | Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság (HU) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011029005-A1 | CRYSTALLINE FORMS OF FESOTERODINE FUMARATE AND FESOTERODINE BASE | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065589-A1 | METHODS OF TREATING OR PREVENTING PRETERM LABOR | ADRB3, CHRNB3, CHRNA3 | CHRM3 4/4885HRH1 2226/4885HTR2A 688/4885 |
| US-20120220655-A1 | CRYSTALLINE FORMS OF FESOTERODINE FUMARATE AND FESOTERODINE BASE | FES, FSHR, SHBG | CHRM3 69/4885HRH1 1244/4885HTR2A 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.